Our detection of HHLA2 in the serum of HCC patients with high tumor HHLA2 expression underscores its potential as a non-invasive liquid biopsy marker for disease monitoring and identifying patients most likely to benefit from c-Met inhibitor therapy, offering a novel approach to precision medicine. Here, MET is linked to hepatocellular carcinoma.